@article{1c6cf48d5aa94fd48af4654611dd49e8,
title = "Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort",
abstract = "Introduction A blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing. Methods We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort. Results Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months (P =.0003) and chemokine-309 (I-309) were increased in AD patients compared to mild cognitive impaired individuals over 36 months (P =.0008). Discussion These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.",
keywords = "Alzheimer's disease, Biomarkers, Blood",
author = "{and the} and {AIBL Research Group} and Gupta, {Veer Bala} and Eugene Hone and Steve Pedrini and James Doecke and Sid O'Bryant and Ian James and Bush, {Ashley I.} and Rowe, {Christopher C.} and Villemagne, {Victor L.} and David Ames and Masters, {Colin L.} and Martins, {Ralph N.}",
note = "Funding Information: The authors thank all the participants who took part in this study and the clinicians who referred participants. The AIBL study (www.AIBL.csiro.au) is a collaboration between CSIRO, Edith Cowan University (ECU), The Florey Institute of Neuroscience and Mental Health (FINMH), National Ageing Research Institute (NARI), and Austin Health. It also involves support from CogState Ltd., Hollywood Private Hospital, and Sir Charles Gairdner Hospital. The study received funding support from CSIRO, Science and Industry Endowment Fund, Alzheimer's Australia (AA), WA Dept. of Health, Brightfocus, USA, and the McCusker Alzheimer's Research Foundation, as well as industry sources. The authors acknowledge the financial support of the CRC for Mental Health, the Cooperative Research Centre (CRC) program is an Australian Government Initiative. Pfizer International has contributed financial support to assist with analysis of blood samples and to further the AIBL research program. Publisher Copyright: {\textcopyright} 2017 The Authors",
year = "2017",
doi = "10.1016/j.dadm.2017.04.003",
language = "English",
volume = "8",
pages = "60--72",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",
}